Antitumor necrosis α treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation

Liver Transpl. 2015 Nov;21(11):1455-6. doi: 10.1002/lt.24212. Epub 2015 Oct 12.

Authors

Polychronis Pavlidis¹, Jonathan Potts², Ashley Barnabas², Nigel Heaton², Ingvar Bjarnason¹, Michael Heneghan², Bu'Hussain Hayee¹

Affiliations

¹ Gastroenterology Department, King's College Hospital, London, UK.
² Institute of Liver Studies, King's College Hospital, London, UK.

PMID: 26175058
DOI: 10.1002/lt.24212

No abstract available

Publication types

Letter

MeSH terms

Adult
Biological Factors / therapeutic use*
Cholangitis, Sclerosing / drug therapy*
Cholangitis, Sclerosing / etiology
Female
Follow-Up Studies
Humans
Inflammatory Bowel Diseases / complications*
Inflammatory Bowel Diseases / drug therapy
Liver Transplantation / adverse effects*
Male
Middle Aged
Postoperative Complications*
Prospective Studies
Time Factors
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Biological Factors
Tumor Necrosis Factor-alpha